Seer (SEER) to Release Quarterly Earnings on Wednesday

Seer (NASDAQ:SEER) will be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Seer to post earnings of ($0.31) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Seer (NASDAQ:SEER) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The company had revenue of $4.44 million during the quarter, compared to analyst estimates of $4.24 million. Seer had a negative return on equity of 20.87% and a negative net margin of 517.84%. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seer Trading Up 3.7 %

SEER opened at $2.24 on Monday. The stock has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.77. Seer has a 12-month low of $1.46 and a 12-month high of $5.65.

Insiders Place Their Bets

In other news, CEO Omid Farokhzad sold 52,857 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $2.03, for a total transaction of $107,299.71. Following the completion of the transaction, the chief executive officer now directly owns 1,436,285 shares in the company, valued at $2,915,658.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.02% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 price objective on shares of Seer in a report on Tuesday, March 5th.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.